+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Regression of new-onset diabetes mellitus after conversion from tacrolimus to cyclosporine in liver transplant patients: results of a pilot study



Regression of new-onset diabetes mellitus after conversion from tacrolimus to cyclosporine in liver transplant patients: results of a pilot study



Clinics and Research in Hepatology and Gastroenterology 35(6-7): 482-488



New-onset diabetes mellitus (NODM) has important implications for long-term outcome following liver transplantation. To evaluate the impact of conversion from tacrolimus to cyclosporine in liver transplant patients presenting NODM. In a 12-month pilot study, 39 liver transplant patients with NODM were converted from tacrolimus to cyclosporine. Most patients (59%) were receiving antidiabetic therapy (18% insulin, 41% oral) and all patients had received dietary advice prior to the study. At month 12, NODM had significantly resolved (FBG<7 mmol/L without treatment) in 36% of patients (95% CI 20.8-51.0%). In the 16 patients not receiving antidiabetic drugs at baseline, mean FBG decreased from 8.1 mmol/L to 6.6 mmol/L (P=0.008) and mean HbA(1c) decreased from 6.4 to 6.0% (P=0.05). Steroids were stopped rapidly in the nine patients receiving steroids at inclusion but NODM resolution was observed in only one of these nine patients. No significant factors were identified that could have affected NODM resolution. There were three episodes of biopsy-proven acute rejection (7.7%), no graft losses and one death. Overall, cyclosporine tolerance was good with no significant change in creatinine clearance at month 12. Total cholesterol increased from 4.6 mmol/L to 5.1 mmol/L (P<0.001). These results suggest that liver transplant patients with NODM may benefit from conversion to cyclosporine from tacrolimus through improved glucose metabolism. Confirmation in a prospective, randomized comparative study is required.

(PDF emailed within 0-6 h: $19.90)

Accession: 055446964

Download citation: RISBibTeXText

PMID: 21530445

DOI: 10.1016/j.clinre.2011.03.008


Related references

Conversion from tacrolimus to cyclosporine in patients with new-onset diabetes after renal transplant: an open-label randomized prospective pilot study. Transplantation Proceedings 47(4): 1158-1161, 2016

Hepatitis C virus viral load after conversion from tacrolimus to cyclosporine in liver transplant patients: a pilot study. Transplantation Proceedings 39(8): 2603-2605, 2007

Conversion from tacrolimus to cyclosporine in liver transplanted patients with diabetes mellitus. Liver Transplantation 12(4): 659-664, 2006

Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation. Transplantation Proceedings 44(9): 2582-2584, 2013

The safety and efficacy of sirolimus and cyclosporine versus tacrolimus in de novo orthotopic liver transplant recipients Results from a pilot study. Hepatology 34(4 Pt 2): 254A, October, 2001

A pilot study of reduced dose cyclosporine and corticosteroids to reduce new onset diabetes mellitus and acute rejection in kidney transplant recipients. Transplantation Research 2(1): 1, 2013

Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation 80(1): 18-25, 2005

Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation. American Journal of Transplantation 18(7): 1726-1734, 2018

Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clinical Transplantation 22(3): 366-371, 2008

Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus. Transplantation Proceedings 42(10): 4573-4577, 2011

Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transplant International 21(2): 146-151, 2007

The safety and efficacy of sirolimus and low-dose tacrolimus versus tacrolimus in de novo orthotopic liver transplant recipients Results from a pilot study. Hepatology 36(4 Part 2): 208A, October, 2002

Analysis of common type 2 diabetes mellitus genetic risk factors in new-onset diabetes after transplantation in kidney transplant patients medicated with tacrolimus. European Journal of Clinical Pharmacology 68(12): 1587-1594, 2013

Immediate conversion from tacrolimus to cyclosporine in the treatment of posttransplantation diabetes mellitus. Transplantation Proceedings 37(2): 999-1000, 2005

Conversion from tacrolimus to cyclosporin is associated with a significant improvement of glucose metabolism in patients with new-onset diabetes mellitus after renal transplantation. Transplantation Proceedings 37(4): 1857-1860, 2005